Hey Malka,
I love the analysis that you have done.
A projected SP of $6.40 at 2025 just for OSA is music to my ears.
Great results for all IHL shareholders today.
Massive actually to think that
80% of trial participants experienced a reduction in AHI levels of greater than 55% to 91.5% during at least one treatment compared to baselineI think all posters can breathe a sigh of relief now that their positive pre-release analysis has been validated.
Congrats to all BOD members and staff.
I am looking forward to some SP appreciation over the coming days and weeks as the PR machine kicks in.
We can now do some real and legitimate comparisons and analyses with RESMED's market share as per
@malkazoid 's post.
Looking forward to the next moves by the BOD
GLAH